Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
Revenue
Ascendis Pharma A/S
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ascendis Pharma A/S
NASDAQ:ASND
|
Revenue
€266.7m
|
CAGR 3-Years
237%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Revenue
kr16.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
40%
|
CAGR 10-Years
38%
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Revenue
kr342.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
55%
|
CAGR 10-Years
48%
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Revenue
kr7.1B
|
CAGR 3-Years
56%
|
CAGR 5-Years
70%
|
CAGR 10-Years
19%
|
Bioporto A/S
CSE:BIOPOR
|
Revenue
kr31m
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
Saniona AB
STO:SANION
|
Revenue
kr16.8m
|
CAGR 3-Years
27%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
See Also
What is Ascendis Pharma A/S's Revenue?
Revenue
266.7m
EUR
Based on the financial report for Dec 31, 2023, Ascendis Pharma A/S's Revenue amounts to 266.7m EUR.
What is Ascendis Pharma A/S's Revenue growth rate?
Revenue CAGR 5Y
91%
Over the last year, the Revenue growth was 421%. The average annual Revenue growth rates for Ascendis Pharma A/S have been 237% over the past three years , 91% over the past five years .